News
DRMA
1.290
+10.26%
0.120
Weekly Report: what happened at DRMA last week (0615-0619)?
Weekly Report · 5d ago
Dermata Therapeutics director Kathleen D. Scott disposes of 11 common shares worth $13.09
PUBT · 06/16 20:16
Weekly Report: what happened at DRMA last week (0608-0612)?
Weekly Report · 06/15 10:21
Weekly Report: what happened at DRMA last week (0601-0605)?
Weekly Report · 06/08 10:17
Weekly Report: what happened at DRMA last week (0525-0529)?
Weekly Report · 06/01 10:21
Dermata Therapeutics Shareholders Approve Equity Plan and Directors
TipRanks · 05/27 22:09
Dermata Therapeutics shareholders approved equity plan share increase to 402,214 at annual meeting
PUBT · 05/27 20:58
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 05/26 21:06
Weekly Report: what happened at DRMA last week (0518-0522)?
Weekly Report · 05/25 10:25
Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4
TipRanks · 05/19 19:45
Weekly Report: what happened at DRMA last week (0511-0515)?
Weekly Report · 05/18 10:24
Dermata Therapeutics GAAP EPS of -$0.48 beats by $0.05
Seeking Alpha · 05/13 20:59
Weekly Report: what happened at DRMA last week (0504-0508)?
Weekly Report · 05/11 10:22
Weekly Report: what happened at DRMA last week (0427-0501)?
Weekly Report · 05/04 10:19
Weekly Report: what happened at DRMA last week (0420-0424)?
Weekly Report · 04/27 10:22
Weekly Report: what happened at DRMA last week (0413-0417)?
Weekly Report · 04/20 10:18
Weekly Report: what happened at DRMA last week (0406-0410)?
Weekly Report · 04/13 10:22
Dermata Therapeutics announces annual shareholder meeting webcast
Reuters · 04/07 10:01
Weekly Report: what happened at DRMA last week (0330-0403)?
Weekly Report · 04/06 10:22
Dermata receives notice of acceptance of Australian patent application
TipRanks · 04/02 12:39
More
Webull provides a variety of real-time DRMA stock news. You can receive the latest news about Dermata Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About DRMA
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.